Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® :

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin...

Related Keywords

Joanne Foody , Sheldon Koenig , Exchange Commission , Twitter , World Congress , Esperion Corporate Communications , Reduced Risk , Major Adverse Cardiovascular Events , Significantly Reduced Risk , Myocardial Infarction , Coronary Revascularization , Broader Outcomes Benefits , Secondary Prevention Compared , Whose Outcomes Studies Were Limited , Only Secondary Prevention , Detailed Results Simultaneously Published , New England Journal , Anticipate Regulatory Filings , Partner Milestone Payments Upon Inclusion , Cardiovascular Risk Reduction Data , Applicable Labels , Conference Call , Discuss Results , American College , Annual Scientific Session , Prescribing Information , Nasdaq Espr , Esperion Therapeutics , Nc ,